Abstract
Facing the challenge of viral mutations in the age of pandemic: Developing highly potent, broad-spectrum, and safe COVID-19 vaccines and therapeutics.
Highlights
Key Laboratory of Medical Molecular Virology (MOE/MOH/CAM), School of Basic Medical Sciences, Shanghai Institute of Infectious Disease and BiosecurityFudan University, Shanghai, China
The COVID-19 Genomics Consortium UK (CoG-UK) found that the number of B.1.1.7-infected cases has grown markedly since September, 2020, and that this lineage can account for an increased proportion of clinical cases in several regions of England.[1]
N501Y in the receptor binding domain (RBD) of the spike (S) protein is reported to be associated with coronavirus adaption to wild-type mice and increased binding affinity to murine angiotensinconverting enzyme 2 (ACE2), the receptor of SARS-CoV2.3 a deep mutational scanning of SARS-CoV2 RBD revealed that N501Y, as well as N501F and N501T, could enhance the affinity of RBD to human ACE2,4 indicating that lineage B.1.1.7 may have increased ability to infect host cells
Summary
The B.1.1.7 lineage contains an unusually large number of genetic changes, more than previous SARS-CoV2 isolates, including 14 non-synonymous mutations and three deletions in ORF1ab, spike protein, ORF8, and nucle-
Sign-in/Register to view highlights & summary Sign-in/Register to access full text options 
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
